C12Y 207/10002
Non-specific protein-tyrosine kinase , i.e. spleen tyrosine kinase
Official title: Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase
C12Y207/10002 (Non-specific protein-tyrosine kinase , i.e. spleen tyrosine kinase) appears on 72 US grants and 183 published applications in this corpus.
Search patents in C12Y- Granted patents
- 72
- Published applications
- 183
- Assignees
- 110
- Inventors
- 452
- Latest grant
- 28 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2005 | 0 | 2 |
| 2006 | 0 | 2 |
| 2007 | 0 | 3 |
| 2008 | 1 | 0 |
| 2009 | 0 | 1 |
| 2010 | 1 | 7 |
| 2011 | 0 | 4 |
| 2012 | 3 | 5 |
| 2013 | 5 | 5 |
| 2014 | 4 | 10 |
| 2015 | 4 | 11 |
| 2016 | 2 | 8 |
| 2017 | 8 | 12 |
| 2018 | 7 | 11 |
| 2019 | 7 | 10 |
| 2020 | 4 | 8 |
| 2021 | 6 | 13 |
| 2022 | 6 | 12 |
| 2023 | 1 | 15 |
| 2024 | 2 | 19 |
| 2025 | 4 | 12 |
| 2026 | 7 | 13 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Methods of treating cancers containing fusion genes28 Jul 2026US 12,692,547 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Compositions and methods related to megakaryocyte-derived extracellular vesicles for treating myeloproliferative neoplasms2 Jun 2026US 12,644,134 B2STRM.bio Incorporated
- Treatment of ocular neovascularization using anti-vegf proteins26 May 2026US 12,636,348 B2Avalanche Australia Pty Ltd.
- Peptide inhibitors of focal adhesion kinase activity and uses thereof26 May 2026US 12,637,492 B2Arizona Board of Regents on Behalf of the University of Arizona
- Surrogate co-receptors for t cells and methods of use17 Mar 2026US 12,577,289 B2Arizona Board of Regents on Behalf of the University of Arizona
- Chk1-targeting sirnas chemically modified with gemcitabine10 Sep 2026US 2026/0265754 A1Sirnaomics, Inc.
- Engineered natural killer cells with enhanced antitumor memory responses3 Sep 2026US 2026/0258360 A1Board of Regents, The University of Texas System
- Phosphorylation-protein complementation assay and related systems and methods13 Aug 2026US 2026/0234576 A1
- Cell6 Aug 2026US 2026/0224627 A1Autolus Limited
- Engineered Plant Virus-Based Nanoparticles and Intravenous Formulations Thereof for Autoimmune Therapy16 Jul 2026US 2026/0199518 A1
Most cited
By later US patents
- Azaindoles useful as inhibitors of janus kinases41US 7,767,816 B2Vertex Pharmaceuticals Incorporated · 2010
- Azaindoles useful as inhibitors of Janus kinases23US 8,163,917 B2Vertex Pharmaceuticals Incorporated · 2012
- Treatment of ocular neovascularization using anti-VEGF proteins20US 10,004,788 B2Avalanche Australia Pty Ltd. · 2018
- Azaindoles useful as inhibitors of janus kinases20US 8,450,489 B2Vertex Pharmaceuticals Incorporated · 2013
- Treatment of ocular neovascularization using anti-VEGF proteins20US 9,943,573 B2Avalanche Australia Pty Ltd. · 2018